A 2026 real-world study followed 120 refractory lupus nephritis patients treated with UC-MSCs. Cumulative renal response reached 56.7% at 12 months with low relapse rates and zero severe adverse events. Here’s what clinicians need to know.
A 36-month clinical trial showed zero adverse events and 57% pain reduction when stem cells were injected into torn rotator cuffs. Here’s what weekend warriors and recreational athletes need to know about MSC therapy for sports injuries.
Every workout floods your bloodstream with stem cells — your body’s own repair crew. Learn how exercise mobilizes regenerative cells and why it matters for aging and healing.
The MERIT phase 1 trial published in Cell Reports Medicine shows that intravenous UC-MSC therapy is safe in subacute ischemic stroke, with early NIHSS improvement signals. Here’s what clinicians need to know.
A 2026 meta-analysis of 15 RCTs shows MSCs cut acute GvHD incidence by 53% and chronic GvHD by 50%. A biomarker-guided trial identifies which transplant patients benefit most — and a cell-free exosome approach may be next.
Your body’s stem cell population drops dramatically after 40. Here’s what the science says about why we age — and how regenerative medicine is fighting back.
Adaptive immunity, also known as acquired immunity or specific immunity, is a subsystem of the overall immune system that provides a tailored defense against specific pathogens. Unlike the innate immune system which offers broad protection, the adaptive immune system is highly specialized to fight each particular pathogen the body encounters.
French 
English 
Chinese 
Russian